UPCI Launches Clinical Trial For Patients With Hereditary Breast And Ovarian Cancers
 

The University of Pittsburgh Cancer Institute (UPCI) will be the primary site for a clinical trial of ABT-888 a drug previously proven in combination treatments to improve chemotherapy's effectiveness by lowering cancer cells' resistance to treatment. This trial will, for the first time, examine ABT-888 as a single agent for patients with cancers related to BRCA 1 or 2 genetic mutations, which predispose patients to breast and ovarian cancers.

More...